Cyprium Therapeutics, a Fortress Biotech Partner Company, and Sentynl Therapeutics, a Wholly- owned Subsidiary of the Zydus Group, Sign Development and Asset Purchase Agreement for Cyprium Therapeutics’ Copper Histidinate Product Candidate for...
This document is hosted externally.
Unless the owner has removed it from the web, you can access the full document via its original URL:
https://sentynl.com/wp-content/uploads/2021/12/2021-02-24-Cyprium-PR-FINAL.pdfUnless the owner has removed it from the web, you can access the full document via its original URL:
See similar contracts (4)
Alternatively, you can try searching for similar contracts:
